Gene therapies for sickle cell disease: final evidence report
- Collection:
- Health Policy and Services Research
- Author(s):
- Beaudoin, Francesca, author Nikitin, Dmitriy, author Campbell, Jonathan D., author McKenna, Avery, author Pearson, Steven D., author Rind, David M., author Thokala, P. (Praveen), author Spackman, David Eldon, author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 21, 2023
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Anemia, Sickle Cell -- therapy Genetic Therapy United States
- Genre(s):
- Technical Report
- Abstract:
- We reviewed the clinical effectiveness of lovotibeglogene autotemcel (lovo-cel) and exagamglogene autotemcel (exa-cel) versus standard of care for the treatment of severe sickle cell disease. We also intended to compare lovo-cel to exa-cel via any evidence directly comparing the two therapies or by indirect comparisons of key outcomes. We sought evidence on patient-important outcomes, including resolution of vaso-occlusive crisis, health-related quality of life, and adverse events.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file ( various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918697383806676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918697383806676